A Phase 1 Multi-Center, Dose-Escalation Study of Vonapanitase Administered Percutaneously to the Superficial Femoral or Popliteal Artery in Patients With Peripheral Artery Disease

Trial Profile

A Phase 1 Multi-Center, Dose-Escalation Study of Vonapanitase Administered Percutaneously to the Superficial Femoral or Popliteal Artery in Patients With Peripheral Artery Disease

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 03 Apr 2017

At a glance

  • Drugs Vonapanitase (Primary)
  • Indications Peripheral arterial disorders
  • Focus Adverse reactions
  • Sponsors Proteon Therapeutics
  • Most Recent Events

    • 30 Mar 2017 Status changed to not yet recruiting.
    • 16 Mar 2016 New trial record
    • 14 Mar 2016 The company plans to initiate this and one other phase I trial in 2016, according to a Proteon Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top